Investigating the effect of mesenchymal stem cells on airway hyper-responsiveness in asthma
Subject Areas : Regenerative Medicine
Kambiz Moghaddasi
1
,
Saeed Hesaraki
2
,
Farnoosh Arfaee
3
,
Seyyed Shamsadin Athari
4
1 - Department of Clinical Sciences, Faculty of Specialized Veterinary Science, Science and Research Branch, Islamic Azad University, Tehran, Iran Department of Clinical Sciences, Faculty of Specialized Veterinary Medicine, Science and Research Branch, Islamic Azad University, Tehran, Iran
2 - Department of Pathobiology, Faculty of Specialized Veterinary Science, Science and Research Branch, Islamic Azad University, Tehran, Iran
3 - Department of Clinical Sciences, Faculty of Specialized Veterinary Science, Science and Research Branch, Islamic Azad University, Tehran, Iran
4 - Department of Immunology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
Keywords: Asthma, Treatment, Lung, Allergy, cell therapy,
Abstract :
Asthma is a lung disease characterized by eosinophilic inflammation, mucus secretion, airway hyper-responsiveness (AHR), and airway obstruction. AHR is a crucial factor in asthma. Mesenchymal stem cells (MSCs) have a regulatory effect on the immune response and may be useful in treating asthma. MSCs have low immunogenicity and are considered safe for application. Additionally, a study was conducted to investigate the effect of MSCs on controlling AHR in an asthma model. MSCs were isolated and used to treat asthmatic male BALB/c mice. To produce an animal model of asthma, the mice were sensitized and challenged with OVA. On days 30 and 40, to measure AHR, a Methacholine challenge test was performed to determine the Penh value. AHR was recorded and analyzed. Treatment of asthmatic mice with MSCs resulted in a significant difference (p<0.05) in controlling AHR during the MCh challenge test. MSCs are almost non-immunogenic and can be used to treat asthma and control AHR. The use of MSCs as an anti-asthma treatment presents a new and applicable strategy for controlling AHR in asthma.
[1] Roxbury CR, Lin SY. Efficacy and safety of subcutaneous and sublingual immunotherapy for allergic rhino conjunctivitis and asthma. Otolaryngologic Clinics of North America. 2017; 50(6): 1111-19.
doi:10.1016/j.otc.2017.08.011
[2] Virchow JC. Allergen immunotherapy (AIT) in asthma. Seminars in Immunology. 2019; 46: 101334.
doi:10.1016/j.smim.2019.101334
[3] Isik E, Fredland NM, Freysteinson WM. School and community-based nurse-led asthma interventions for school-aged children and their parents: a systematic literature review. Journal of Pediatric Nursing. 2019; 44: 107-14.
doi:10.1016/j.pedn.2018.11.007
[4] Xuan X, Sun Z, Yu C, Chen J, Chen M, Wang Q. et al. Network pharmacology-based study of the protective mechanism of conciliatory anti-allergic decoction on asthma. Allergologia et Immunopathologia (Madr). 2020; 48: 441-9.
doi:10.1016/j.aller.2019.12.011
[5] Sopo SM, Bersani G, Del Vescovo E, Gelsomino M. Disagreement between guidelines regarding the third step of asthma drug therapy for school-age children. Allergologia et Immunopathologia (Madr). 2020; 48: 789-91.
doi:10.1016/j.aller.2019.12.004
[6] Huang M, Mehrabi Nasab E, Athari SS. Immunoregulatory effect of mesenchymal stem cell via mitochondria signaling pathways in allergic asthma. Saudi Journal of Biological Sciences. 2021; 28: 6957-62.
doi:10.1016/j.sjbs.2021.07.071
[7] Hou C, Sun F, Liang Y, Mehrabi Nasab E, Athari SS. Effect of transduced mesenchymal stem cells with IL-10 gene on control of allergic asthma. Allergologia et Immunopathologia (Madr). 2023; 51(2): 45-51. doi:10.15586/aei.v51i2.789
[8] Cheng C, Mehrabi Nasab E, Athari SS. Survey of immunopharmacological effects of botulinum toxin in cell signaling of bronchial smooth muscle cells in allergic asthma. Allergologia et Immunopathologia (Madr). 2022; 50(3): 93-100.
doi:10.15586/aei.v50i3.549
[9] Jiang J, Mehrabi Nasab E, Athari SM, Athari SS. Effects of vitamin E and selenium on allergic rhinitis and asthma pathophysiology. Respiratory Physiology & Neurobiology 2021; 286: 103614. doi:10.1016/j.resp.2020.103614
[10] Tanaka H, Komai M, Nagao K, Ishizaki M, Kajiwara D, Takatsu K. et al. Role of interleukin-5 and eosinophils in allergen-induced airway remodeling in mice. American Journal of Respiratory Cell and Molecular Biology. 2004; 31(1): 62-68. doi:10.1165/rcmb.2003-0305OC
[11] Booth BW, Sandifer T, Martin EL, Martin LD. IL-13-induced proliferation of airway epithelial cells: mediation by intracellular growth factor mobilization and ADAM17. Respiratory Research. 2007; 8: 51.
[12] Ouyang Y, Miyata M, Hatsushika K, Ohnuma Y, Katoh R, Ogawa H. et al. TGF-beta signaling may play a role in the development of goblet cell hyperplasia in a mouse model of allergic rhinitis. Allergology International. 2010; 59(3): 313-19.
doi:10.2332/allergolint.10-SC-0172
[13] Samitas K, Delimpoura V, Zervas E, Gaga M. Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectives. European Respiratory Review. 2015; 24(138): 594-601. doi:10.1183/16000617.00001715
[14] Yin J, Yan F, Zheng R, Wu X, Athari SS. Immunomodulatory effect of IL-2 induced bone marrow mononuclear cell therapy on control of allergic asthma. Allergologia et Immunopathologia (Madr). 2023; 51(1): 110-15. doi:10.15586/aei.v51i1.746
[15] Cruz FF, Borg ZD, Goodwin M, Sokocevic D, Wagner DE, Coffey A. et al. Systemic administration of human bone marrow derived mesenchymal stromal cell extracellular vesicles ameliorates aspergillus hyphal extract induced allergic airway inflammation in immunocompetent mice. Stem Cells Translational Medicine. 2015; 4(11): 1302-16.
doi:10.5966/sctm.2014-0280
[16] Lathrop MJ, Brooks EM, Bonenfant NR, Sokocevic D, Borg ZD, Goodwin M. et al. Mesenchymal stromal cells mediate aspergillus hyphal extract-induced allergic airway inflammation by inhibition of the Th19 signaling pathway. Stem Cells Translational Medicine. 2014; 3(2): 194-205.
doi:10.5966/sctm.2013-0061
[17] Hu X, Yu SP, Fraser JL, Lu Z, Ogle ME, Wang JA. et al. Transplantation of hypoxia preconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis. Journal of Thoracic and Cardiovascular Surgery. 2008; 135(4): 799-808.
doi: 10.1016/j.jtcvs.2007.07.071
[18] Urbanek K, de Angelis A, Spaziano G, Piegari E, Matteis M, Cappetta D. et al. Intratracheal administration of mesenchymal stem cells modulates tachykinin system, suppresses airway remodeling and reduces airway hyperresponsiveness in an animal model. Plos One. 2016; 11(7):e0158746.
doi:10.1371/journal.pone.0158746
[19] Lin YD, Fan XL, Zhang H, Fang SB, Li CL, Deng MX. et al. The genes involved in asthma with the treatment of human embryonic stem cell-derived mesenchymal stem cells. Molecular Immunology. 2018; 95: 47-55.
doi:10.1016/j.molimm.2018.01.013
[20] Zhang R, Yin Z, Pan J, Zhai C, Athari SS, Dong L. Effect of transfected induced pluripotent stem cells with Decorin gene on control of lung remodeling in allergic asthma. Journal of Investigative Medicine 2023, Vol. 71(3): 235-43.
doi:10.1177/10815589221140590
[21] Bao ZH, Gao F, Athari SS, Wang H. Immunomodulatory effect of IL-35 gene-transfected mesenchymal stem cells on allergic asthma. Fundamental & Clinical Pharmacology. 2023; 37(1): 116-124. doi:10.1111/fcp.12823